TITLE
The BET Bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs

ORGANISM
Homo sapiens

SUMMARY
assess the efficacy of OTX015, a BET Bromodomain inhibitor,with respect to various lymphoma models, and to characterize its mechanism of action

DESIGN
GEP analysis of 2 lymphoma cell lines with and without treatment with BET Inhibitor and 22 lymphoma cell lines without treatment (basal level).

